CoChat

Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis

Liu, Ligang, Shi, Hekai, Shi, Yufei, Wang, Anlin, Guo, Nuojin, Tao, Heqing, Nahata, Milap C. · 2024 · Pharmaceuticals
Cited by 40

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Four glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used in children and adolescents with obesity or overweight. This network meta-analysis was conducted to compare the efficacy and safety of these regimens. Embase, PubMed, and Scopus were searched on March 2023 and updated in June 2024 for eligible randomized controlled trials (RCTs). The primary efficacy outcomes were mean difference in actual body weight, BMI (body mass index), BMI z score, and waist circumference. Safety outcomes included nausea, vomiting, diarrhea, abdominal pain, injection-site reaction, and hypoglycemia. Eleven RCTs with 953 participants were eligible. Semaglutide exhibited greater effects in reducing weight, BMI, and BMI z score versus the placebo. Semaglutide was associated with greater weight loss and BMI z score reduction in comparison with exenatide, liraglutide, and dulaglutide. Semaglutide also significantly decreased BMI than exenatide. None of the four GLP-1 RAs were associated with higher risks of diarrhea, headache, and abdominal pain versus the placebo. Liraglutide was more likely to cause nausea, vomiting, hypoglycemia, and injection-site reactions than the placebo. Liraglutide also had higher odds of causing injection-site reactions than other GLP-1 RAs. Semaglutide appeared to be the most effective and safe option among four GLP-1 RAs in children and adolescents with obesity or overweight.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph17070828

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Simmonds, 2016, Predicting adult obesity from childhood obesity: A systematic review and meta-analysis, Obes. Rev., 17, 95, 10.1111/obr.12334 · DOI · Paper page
  2. Rahmouni, 2005, Obesity-associated hypertension: New insights into mechanisms, Hypertension, 45, 9, 10.1161/01.HYP.0000151325.83008.b4 · DOI · Paper page
  3. Lister, 2023, Child and adolescent obesity, Nat. Rev. Dis. Primers, 9, 24, 10.1038/s41572-023-00435-4 · DOI · Paper page
  4. Grossman, 2017, Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 2417, 10.1001/jama.2017.6803 · DOI · Paper page
  5. Skinner, 2023, Appraisal of Clinical Care Practices for Child Obesity Treatment. Part I: Interventions, Pediatrics, 151, e2022060642, 10.1542/peds.2022-060642 · DOI
  6. Woodard, 2020, Medications for the treatment of obesity in adolescents, Ther. Adv. Endocrinol. Metab., 11, 2042018820918789, 10.1177/2042018820918789 · DOI · Paper page
  7. Gourgari, 2021, Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers’ perspectives, Pediatr. Diabetes, 22, 872, 10.1111/pedi.13234 · DOI
  8. Apperley, 2022, Childhood obesity: A review of current and future management options, Clin. Endocrinol., 96, 288, 10.1111/cen.14625 · DOI
  9. Ryan, 2021, Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis, J. Pediatr., 236, 137, 10.1016/j.jpeds.2021.05.009 · DOI · Paper page
  10. Arslanian, 2022, Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes, N. Engl. J. Med., 387, 433, 10.1056/NEJMoa2204601 · DOI · Paper page
  11. Klein, 2014, Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial, Diabetes Technol. Ther., 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
  12. Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N. Engl. J. Med., 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
  13. Danne, 2017, Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12–17 Years, J. Pediatr., 181, 146, 10.1016/j.jpeds.2016.10.076 · DOI · Paper page
  14. Mastrandrea, 2019, Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, Pediatr. Obes., 14, e12495, 10.1111/ijpo.12495 · DOI · Paper page
  15. Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr. Obes., 15, e12624, 10.1111/ijpo.12624 · DOI · Paper page
  16. Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: A randomized, placebo-controlled, clinical trial, JAMA Pediatr., 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
  17. Fox, 2022, Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial, Obesity, 30, 1105, 10.1002/oby.23395 · DOI
  18. Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study, Obesity, 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
  19. Holst, 2017, Semaglutide seems to be more effective the other GLP-1Ras, Ann. Transl. Med., 5, 505, 10.21037/atm.2017.11.10 · DOI · Paper page
  20. Drozdz, D., Alvarez-Pitti, J., Wójcik, M., Borghi, C., Gabbianelli, R., Mazur, A., Herceg-Čavrak, V., Lopez-Valcarcel, B.G., Brzeziński, M., and Lurbe, E. (2021). Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. Nutrients, 13. · DOI · Paper page
  21. Clifton, 2018, Relationship Between Changes in Fat and Lean Depots Following Weight Loss and Changes in Cardiovascular Disease Risk Markers, J. Am. Heart Assoc., 7, e008675, 10.1161/JAHA.118.008675 · DOI
  22. Vanderwall, C., Randall Clark, R., Eickhoff, J., and Carrel, A.L. (2017). BMI is a poor predictor of adiposity in young overweight and obese children. BMC Pediatr., 17. · DOI · Paper page
  23. Overgaard, 2021, Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes, Cell Rep. Med., 2, 100387, 10.1016/j.xcrm.2021.100387 · DOI · Paper page
  24. Zhao, 2022, Comparison of weight loss and adverse events of obesity drugs in children and adolescents: A systematic review and meta-analysis, Expert. Rev. Clin. Pharmacol., 15, 1119, 10.1080/17512433.2022.2117152 · DOI
  25. 2015, Rebound effect of intervention programs to reduce overweight and obesity in children and adolescents systematic review, Nutr. Hosp., 32, 2508
  26. Mamrot, 2019, The association of the executive functions with overweight and obesity indicators in children and adolescents: A literature review, Neurosci. Biobehav. Rev., 107, 59, 10.1016/j.neubiorev.2019.08.021 · DOI · Paper page
  27. Liang, J.H., Zhao, Y., Chen, Y.C., Jiang, N., Zhang, S.X., Huang, S., Kakaer, A., and Chen, Y.J. (2022). Face-to-face physical activity incorporated into dietary intervention for overweight/obesity in children and adolescents: A Bayesian network meta-analysis. BMC Med., 20. · DOI
  28. Epstein, 2023, Family-Based Behavioral Treatment for Childhood Obesity Implemented in Pediatric Primary Care: A Randomized Clinical Trial, JAMA, 329, 1947, 10.1001/jama.2023.8061 · DOI
  29. Sadry, 2013, Emerging combinatorial hormone therapies for the treatment of obesity and T2DM, Nat. Rev. Endocrinol., 9, 425, 10.1038/nrendo.2013.47 · DOI · Paper page
  30. Liu, L., Nahata, M., Shi, H., Sun, Y., and Xie, M. (2024, April 01). Efficacy and Safety of Tirzepatide in Overweight or Obese Adults without Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Preprint (Version 1). Available online: https://www.researchsquare.com/article/rs-4184273/v1. · DOI
  31. Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy, Obesity, 17, 1736, 10.1038/oby.2009.184 · DOI · Paper page
  32. Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. · DOI · Paper page
  33. Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations, Ann. Intern. Med., 162, 777, 10.7326/M14-2385 · DOI · Paper page

Cited by

See all 40

Metadata

Authors
Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C.
Affiliations
  • Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
  • Department of Bariatric and Metabolic Surgery, Fudan University Affiliated Huadong Hospital, Shanghai 201203, China
  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 200437, China
  • Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100054, China
  • Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200331, China
  • Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2024-06-24
Volume
17
Issue
7
Pages
828
ISSN
1424-8247
Cited by
40
References
22
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.